Regeneron Reports Third-Quarter EPS of $18.45

Regeneron reported third-quarter 2026 revenue of $5.1 billion, up 36% from a year earlier. GAAP diluted EPS rose 35% to $18.45, while non-GAAP diluted EPS increased 70% to $20.07. The company also announced an expanded Sanofi collaboration and FDA approval of Pasatru for fibrodysplasia ossificans p…